SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 4 — Focused Visit (Follow-up) — Clara Barton

PatientClara Barton
Date of birth1973-12-25
IdentifiersMRN HR-NI024-SYN; SSN (made up) 000-24-3357
Document date2026-04-14
AuthorEleanor Whitcombe, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Twelve-week depression treatment review. [S]

History of Present Illness

Ms. Barton returns six weeks after sertraline was increased to 100 mg. At the nurse telephone check two weeks after the increase she reported three days of mild nausea and no restlessness or suicidal thoughts. She now has more good days than bad, enjoys her work again, and sleeps about six and a half hours. She has had ten CBT sessions and is using the sleep schedule. She increased to 35 hours a week after the last visit and this week to her new limit of 45 hours, and she has handed the families' correspondence to a colleague. She has missed no doses and has had no side effects since the first few days after the increase. She has had no suicidal thoughts. [S]

ElementDetail
Interval changeMore good days than bad; enjoying work again
Dose increaseThree days of mild nausea after the increase; nurse check at two weeks with no concerns
SleepAbout six and a half hours
WorkUp to 45 hours a week; correspondence delegated
SafetyNo suicidal thoughts
PHQ-97, down from 18

Review of Systems

SystemResultFinding
ConstitutionalNegativeEnergy better; weight up 1.1 kg since intake
GastrointestinalNegativeNo nausea now; no bleeding
GenitourinaryNegativeNo sexual side effects
PsychiatricPositiveMild residual low energy on some days; no suicidal thoughts, elevated mood, or racing thoughts

4 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Sertraline 50 mg oral tablet, one tablet by mouth each morningOne tablet by mouth each morningOral route2026-01-20 to 2026-03-03completedS
Sertraline 100 mg oral tablet, one tablet by mouth each morningOne tablet by mouth each morningOral route2026-03-03activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-04-14Body height152cmS
2026-04-14Body weight50.9kgS
2026-04-14Body mass index (BMI) [Ratio]22kg/m2S
2026-04-14Systolic blood pressure118mm[Hg]S
2026-04-14Diastolic blood pressure74mm[Hg]S
2026-04-14Heart rate72/minS
2026-04-14Respiratory rate14/minS
2026-04-14Body temperature36.6CelS
2026-04-14Oxygen saturation in Arterial blood by Pulse oximetry99%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-04-14Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]7{score}S
2026-04-14Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ]4{score}S

Physical Exam

Vital signs recorded on 2026-04-14; see the Vital Signs section. [S]

SystemFinding
GeneralWell groomed; brisk
Mental statusAlert; mood "much better"; affect reactive with humor; thought process linear; no suicidal ideation; insight and judgment good

Problems

ProblemClinical statusVerificationCodeProvenance
Major depressive disorder, recurrent, moderate (moderately severe symptoms at intake), after a prolonged humanitarian deployment; synthetic modern diagnosis linked to her documented periods of depression and nervous prostrationactiveconfirmed F33.1S — Synthetic modern diagnosis. Her periods of depression and nervous prostration are documented in her own words (D); calling them major depression is a retrospective interpretation (R), and no diagnosis was made in her lifetime.
Occupational burnout after eighteen months leading field medical relief in a war zoneactiveconfirmed Z73.0S — Synthetic contributing factor echoing her documented exhaustion after wartime relief work; burnout is an occupational phenomenon, not a mental disorder.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
SurveyPHQ-9Baseline, then at least monthly during acute treatment; every 2 to 4 weeks in continuationCompleted today7, down 61 percent from 18: response; remission not yet reached
SurveyGAD-7With the PHQ-9 when anxiety symptoms were present at baselineCompleted today4, down from 9
SurveySuicide risk reassessment (C-SSRS Since Last Visit and PHQ-9 item 9)Every visit during active treatmentCompleted todayNo suicidal thoughts, intent, plan, or behavior since the last visit; PHQ-9 item 9 scored 0. Safety plan reviewed
Medication safetyTolerability check two weeks after the dose increase2 weeks after each dose changeCompleted todayDone by nurse telephone call two weeks after the increase: three days of mild nausea, no activation or suicidal thoughts
Medication safetyAdherence and adverse-effect reviewEvery visit during active treatmentCompleted todayNo missed doses; no side effects now
Self-managementPsychotherapy, sleep, work hours, and social contactEvery visit during active treatmentCompleted todayTen CBT sessions; sleep about six and a half hours; 45-hour week; peer support group advised
LaboratoryLithium, anticonvulsant, or antipsychotic monitoring (levels, metabolic tests, AIMS)Only on those drugsNot indicatedTreated with an SSRI only

Goal progress:

Guideline basis: VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder (2022); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026)

Follow-up: Care-manager telephone PHQ-9 in about four weeks; depression review in two months. Next scheduled visit 2026-06-16: five-month depression review in continuation treatment. [S]